Vericel Corporation (VCEL)

In Q3 2025, Vericel reported record results with $67.5 million in total revenue, driven by a 25% increase in MACI revenue. Preliminary full-year 2025 results indicated approximately $276 million in total net revenue. Vericel received a BARDA contract for NexoBrid valued at up to $197 million. Management provided 2026 guidance, targeting total revenue of $316–$326 million. Vericel won FDA approval for a new advanced therapy manufacturing facility.

Vericel Corporation experiences demand seasonality for its products, with seasonally stronger orthopedic volumes in the second half of the year. A single quarter's sales have ranged from 17% to 34% of annual volumes, indicating significant fluctuations. The company's ability to predict and meet demand, manage inventory efficiently, and control expired inventory are factors affected by these seasonal variations.

Vericel Corporation is a commercial-stage biopharmaceutical company specializing in advanced autologous cell therapies for sports medicine and severe burn care markets. The company focuses on developing, manufacturing, and marketing patient-specific treatments. Its primary revenue streams are generated through sports medicine and burn care franchises. Major products include MACI, an FDA-approved cell therapy for knee cartilage defects; Epicel, a permanent skin replacement for severe burns; and NexoBrid, approved for enzymatic eschar removal in burn patients.

Vericel Corporation's geographical market presence is predominantly concentrated within North America, specifically the United States. The company's key products are marketed and distributed exclusively within this domestic market. Vericel aims to deepen its market share within the U.S. by expanding its sales force and exploring new orthopedic markets within the U.S. While its primary focus is the U.S., Vericel has previously licensed its product portfolio for distribution in China, South Korea, and other Southeast Asian countries.

Vericel maintains a strong brand reputation within the biopharmaceutical industry, particularly in sports medicine and burn care. Consistent top-line growth and achieving GAAP net income in 2024 and 2025 demonstrates financial stability. FDA approval for MACI Arthro enhances the product's appeal. The BARDA contract for NexoBrid strengthens the company's position in the burn care market. Vericel's investment in surgeon training programs and manufacturing processes contribute to product adoption. FDA approval for a new manufacturing facility solidifies the company's operational capabilities.

Vericel Corporation's ownership is largely concentrated among institutional investors, who held approximately 75,008,654 shares as of August 20, 2025. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., and State Street Corp. Consonance Capital Management LP is the largest individual shareholder, owning 4.40% of the company. Insider ownership is relatively small, around 1.06% to 8.82%.